Business
Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7 Million
EXPAREL achieves record net product sales of $506.5 million for the full-year, $139.9 million for the fourth quarter, and $50.9 million for the month of
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"EXPAREL achieves record net product sales of $506.5 million for the full-year, $139.9 million for the fourth quarter, and $50.9 million for the month of December\nTAMPA, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $540.7 to $541.7 million for 2021, compared with $429.6 million for 2020, representing an increase of at least 25.8%. The company’s 2021 revenue includes net product sales of EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera°® system. Pacira began recognizing sales of ZILRETTA in November 2021 after completing its previously announced acquisition of Flexion Therapeutics, Inc. “2021 was a very successful year for Pacira marked by record level sales for EXPAREL, the addition of ZILRETTA to our commercial offering, and significant growth in iovera° revenue and customers,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “For the first three weeks of December, year-over-year EXPAREL sales growth was in the low teens, with the last week of the year impacted by a slowdown in elective procedures as regional surges in Omicron cases prompted government restrictions and escalated staffing challenges.” “Expediting surgical recovery is more critical than ever and long-acting field and nerve blocks with EXPAREL are transforming the field of regional anesthesia, enabling earlier discharge, and migrating elective procedures to 23-hour sites of care. We continue to support the market’s ongoing shift to anesthesia-driven postsurgical pain management through robust educational and training initiatives that are driving demand within our orthopedic, general surgery, cardiothoracic, women’s health and pediatric franchises. Looking ahead, we believe we are well positioned to continue to deliver strong top- and bottom-line growth as we advance innovative non-opioid options to redefine patient care along the neural pain pathway,” continued Mr. Stack. Fourth Quarter and December 2021 Preliminary Revenue Highlights EXPAREL net product sales were $139.9 million and $125.3 million for the fourth quarters of 2021 and 2020 and $50.9 mil...